Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that on August 22, the Company launched ASTHPHYLLIN S
, a consumer health care medication to alleviate asthma, coughing and expectoration of sputum.
is an OTC (over-the-counter) version of ASTHPHYLLIN
, an antiasthmatic drug for prescription use and has been developed to fit the Japanese non-prescription drug approval standards for its therapeutic category.
contains diprophylline and dl-methylephedrine hydrochloride to dilate constricted bronchial tubes and widen airways, making it easier to expectorate, in addition to noscapine which acts on the part of the central nervous system responsible for coughing, and diphenhydramine hydrochloride to relieve allergic asthma and coughing. These ingredients work together and can control coughing triggered by allergic inflammation in the mucous membranes of the respiratory tract, which is a key factor in asthma, and the nighttime coughing which is characteristic of the disease.
Eisai hopes ASTHPHYLLIN S
will help people suffering from asthma, coughing or sputum expectoration.
[The product outline and photograph are attached for reference.]
Eisai Co., Ltd.
Corporate Communications Department
Phone 03-3817-5120 (Tokyo)